HRMY

HARMONY BIOSCIENCES HOLDINGS, INC.

Company Overview

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

SectorHealthcare
IndustryBiotechnology
Market Cap$2.4B
Employees293
CEOJeffrey Dayno

Valuation

Current Price$42.25
Fair Value?$000.00
Valuation?Overvalued
Hist. PE ?13.81
EPS (TTM) ?3.13
Forward EPS Growth ?9.48%
Historical Growth ?59.40%
Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro

Price

Unlock Fair Value line — Pro

EPS

Revenue

Equity

Pro

Available on the Pro plan

Free Cash Flow

Pro

Available on the Pro plan

Long Term Debt

Pro

Available on the Pro plan

Net Profit

Pro

Available on the Pro plan

Shares Outstanding

Pro

Available on the Pro plan

Last updated: 9/5/2026, 6:21:30 PM